Discovery of U2AF1 neoantigens in myeloid neoplasms.
Autorzy:
Biernacki MA; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA .; Department of Medicine, University of Washington, Seattle, Washington, USA. Lok J; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Black RG; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Foster KA; Department of Immunology, University of Washington, Seattle, Washington, USA. Cummings C; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Woodward KB; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Monahan T; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. OehlerVG; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA. Stirewalt DL; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA. Wu D; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA. Rongvaux A; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Deeg HJ; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA. Bleakley M; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
Autorzy:
Zarling LC; Department of Medicine, University of Washington, Seattle, Washington, DC, USA. Stevenson PA; Clinical Statistics Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Soma LA; Department of Pathology, City of Hope National Medical Center, Duarte, California, USA. Martino CH; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Percival MM; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Halpern AB; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Ghiuzeli CM; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Becker PS; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA. OehlerVG; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Cooper JP; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Orozco JJ; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Hendrie PC; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Walter RB; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Estey EH; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA. Cassaday RD; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2023 Dec; Vol. 111 (6), pp. 863-871. Date of Electronic Publication: 2023 Sep 05.
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Autorzy:
Winn AN; Department of Health Systems, Outcomes and Policy, School of Pharmacy, University of Illinois at Chicago. Atallah E; Department of Medicine, Medical College of Wisconsin, Milwaukee. Cortes J; Georgia Cancer Center, Augusta University Medical Center, Augusta. Deininger MWN; Department of Medicine, Medical College of Wisconsin, Milwaukee. Kota V; Georgia Cancer Center, Augusta University Medical Center, Augusta. Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, Illinois. Moore JO; Duke University School of Medicine, Durham, North Carolina. Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, New York. OehlerVG; Fred Hutchinson Cancer Research Center, Seattle, Washington. Pinilla-Ibarz J; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. Radich JP; Fred Hutchinson Cancer Research Center, Seattle, Washington. Shah NP; Department of Medicine, University of California at San Francisco. Thompson JE; Roswell Park Comprehensive Cancer Center, Buffalo, New York. Flynn KE; Department of Medicine, Medical College of Wisconsin, Milwaukee.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2023 Dec 01; Vol. 6 (12), pp. e2347950. Date of Electronic Publication: 2023 Dec 01.
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Autorzy:
Flynn KE; Medical College of Wisconsin, Milwaukee, WI. . Atallah E; Medical College of Wisconsin, Milwaukee, WI. Lin L; Duke University School of Medicine, Durham, NC. Shah NP; University of California at San Francisco, San Francisco, CA. Silver RT; Weill Cornell Medicine, New York, NY. Larson RA; University of Chicago, Chicago, IL. Panilla-Ibarz J; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Thompson JE; Roswell Park Comprehensive Cancer Center, Buffalo, NY. OehlerVG; Fred Hutchinson Cancer Research Center, Seattle, WA. Radich JP; Fred Hutchinson Cancer Research Center, Seattle, WA. Kota V; Georgia Cancer Center at Augusta University, Augusta, GA. Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, NY. Schiffer CA; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI. Cortes J; Georgia Cancer Center at Augusta University, Augusta, GA. Weinfurt KP; Duke University School of Medicine, Durham, NC.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2022 Nov 01; Vol. 107 (11), pp. 2641-2649. Date of Electronic Publication: 2022 Nov 01.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
Autorzy:
Godwin CD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Rodríguez-Arbolí E; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Halpern AB; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Appelbaum JS; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Percival MM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Hendrie PC; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. OehlerVG; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Keel SB; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Abkowitz JL; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Cooper JP; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Estey EH; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA 98195, USA.; Department of Epidemiology, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Jun 14; Vol. 14 (12). Date of Electronic Publication: 2022 Jun 14.
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
Autorzy:
Garcia KA; Department of Medicine, University of Washington, Seattle, Washington. Cherian S; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington. Stevenson PA; Clinical Statistics Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Biostatistics, University of Washington, Seattle, Washington. Martino CH; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington. Shustov AR; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Becker PS; Department of Medicine, University of Washington, Seattle, Washington.; Department of Medicine, University of California Irvine, Irvine, California. Percival MM; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. OehlerVG; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Halpern AB; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Walter RB; Department of Medicine, University of Washington, Seattle, Washington.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Orozco JJ; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Keel SB; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington. Estey EH; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Cassaday RD; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Pokaż więcej
Źródło:
Cancer [Cancer] 2022 Apr 01; Vol. 128 (7), pp. 1411-1417. Date of Electronic Publication: 2021 Dec 21.
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
Autorzy:
Palmieri R; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA. Buckley SA; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA. Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Halpern AB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. Percival MM; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. Scott BL; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. Hendrie PC; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Seattle Cancer Care Alliance, Seattle, WA, USA. Becker PS; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. OehlerVG; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Department of Pathology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jul; Vol. 61 (7), pp. 1728-1731. Date of Electronic Publication: 2020 Feb 20.
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis.
Autorzy:
Godavarthy PS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany. Kumar R; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany. Herkt SC; Institute for Transfusion Medicine DRK- Blutspendedienst Baden-Württemberg - Hessen, Frankfurt am Main, Germany. Pereira RS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany. Hayduk N; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany. Weissenberger ES; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany. Aggoune D; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany. Manavski Y; Institute of Cardiovascular Regeneration, Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany. Lucas T; Institute of Cardiovascular Regeneration, Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany. Pan KT; Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany. Voutsinas JM; Fred Hutchinson Cancer Research Center, Clinical Research Division, Biostatistics, Seattle, WA, USA. Wu Q; Fred Hutchinson Cancer Research Center, Clinical Research Division, Biostatistics, Seattle, WA, USA. Müller MC; Institute for Hematology and Oncology, Mannheim, Germany. Saussele S; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. Oellerich T; Department of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt am Main, Germany.; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany. OehlerVG; Fred Hutchinson Cancer Research Center, Clinical Research Division, Division of Hematology, University of Washington Medical Center, Seattle, WA, USA. Lausen J; Institute for Transfusion Medicine DRK- Blutspendedienst Baden-Württemberg - Hessen, Frankfurt am Main, Germany. Krause DS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany .; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.; Faculty of Medicine, Johann Wolfgang Goethe University, Frankfurt.; Frankfurt Cancer Institute, Frankfurt, Germany.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2020 Jan; Vol. 105 (1), pp. 136-147. Date of Electronic Publication: 2019 Apr 24.
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Autorzy:
Halpern AB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington. Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center. Huebner EM; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington. Scott BL; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Medical Oncology, University of Washington. Hendrie PC; Department of Medicine, Division of Hematology, University of Washington.; Seattle Cancer Care Alliance. Percival MM; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington. Becker PS; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington. Smith HA; Seattle Cancer Care Alliance. OehlerVG; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington. Orozco JJ; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington. Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington. Gardner KM; Department of Medicine, Division of Hematology, University of Washington. Chen TL; Deparment of Pharmacy Services, University of Washington. Buckley SA; Hematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center. Orlowski KF; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington. Anwar A; Hematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center. Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington .; Department of Medicine, Division of Hematology, University of Washington.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2019 Apr; Vol. 104 (4), pp. e143-e146. Date of Electronic Publication: 2018 Nov 08.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Autorzy:
Cortes JE; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas. Douglas Smith B; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. Wang ES; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York. Merchant A; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. OehlerVG; Fred Hutchinson Cancer Research Center, Seattle, Washington. Arellano M; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia. DeAngelo DJ; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Pollyea DA; Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado. Sekeres MA; Leukemia Program, Cleveland Clinic, Cleveland, Ohio. Robak T; Department of Hematology, Medical University of Lodz, Lodz, Poland. Ma WW; Pfizer Oncology, New York, New York. Zeremski M; Pfizer Oncology, New York, New York. Naveed Shaik M; Pfizer Oncology, New York, New York. Douglas Laird A; Pfizer Oncology, New York, New York. O'Connell A; Pfizer Oncology, New York, New York. Chan G; Pfizer Oncology, New York, New York. Schroeder MA; Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2018 Nov; Vol. 93 (11), pp. 1301-1310. Date of Electronic Publication: 2018 Sep 09.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Autorzy:
Atallah E; Department of Medicine, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA. Schiffer CA; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. Weinfurt KP; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. Zhang MJ; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA. Radich JP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. OehlerVG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Pinilla-Ibarz J; Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Deininger MWN; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA. Lin L; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA. Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Moore JO; Duke Cancer Institute, Durham, NC, USA. Ritchie EK; Weill Medical College of Cornell University, New York, NY, USA. Shah NP; Department of Medicine, University of California at San Francisco, San Francisco, CA, USA. Silver RT; Weill Medical College of Cornell University, New York, NY, USA. Wadleigh M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Cortes J; University of Texas MD Anderson Cancer Center, Houston, TX, USA. Thompson J; Roswell Park Cancer Institute, Buffalo, NY, USA. Guhl J; Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA. Horowitz MM; Department of Medicine, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA. Flynn KE; Department of Medicine, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Apr 02; Vol. 18 (1), pp. 359. Date of Electronic Publication: 2018 Apr 02.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
Autorzy:
Lee SI; Paul G. Allen School of Computer Science and Engineering, University of Washington, 185 E Stevens Way NE, Seattle, WA, 98195, USA. .; Department of Genome Sciences, University of Washington, 3720 15th Ave NE, Seattle, WA, 98195, USA. .; Center for Cancer Innovation, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. . Celik S; Paul G. Allen School of Computer Science and Engineering, University of Washington, 185 E Stevens Way NE, Seattle, WA, 98195, USA. Logsdon BA; Sage Bionetworks, 1100 Fairview Ave N, Seattle, WA, 98109, USA. Lundberg SM; Paul G. Allen School of Computer Science and Engineering, University of Washington, 185 E Stevens Way NE, Seattle, WA, 98195, USA. Martins TJ; Quellos High Throughput Screening Core, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. OehlerVG; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. Miller CP; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. Chien S; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. Dai J; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. Saxena A; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. Blau CA; Center for Cancer Innovation, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. Becker PS; Center for Cancer Innovation, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2018 Jan 03; Vol. 9 (1), pp. 42. Date of Electronic Publication: 2018 Jan 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Autorzy:
Ramamurthy R; University of Washington School of Medicine, Seattle, Washington. Hughes M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Children's Hospital, Seattle, Washington. Morris V; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Bolouri H; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Gerbing RB; Children's Oncology Group, Monrovia, California. Wang YC; Children's Oncology Group, Monrovia, California. Loken MR; Hematologics, Inc, Seattle, Washington. Raimondi SC; Children's Oncology Group, Monrovia, California.; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee. Hirsch BA; Children's Oncology Group, Monrovia, California.; Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota. Gamis AS; Children's Oncology Group, Monrovia, California.; Children's Mercy Hospitals & Clinics, Kansas City, Missiouri. OehlerVG; University of Washington School of Medicine, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Alonzo TA; Keck School of Medical Department of Preventive Medicine, University of Southern California, Los Angeles, California. Meshinchi S; University of Washington School of Medicine, Seattle, Washington. .; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. .; Seattle Children's Hospital, Seattle, Washington. .; Children's Oncology Group, Monrovia, California. .
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2016 Dec; Vol. 63 (12), pp. 2096-2103. Date of Electronic Publication: 2016 Aug 11.
CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.
Autorzy:
Bajaj J; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Konuma T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Lytle NK; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Kwon HY; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Ablack JN; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Cantor JM; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Rizzieri D; Division of Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Chuah C; Department of Haematology, Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore 169857, Singapore. OehlerVG; Clinical Research Division, Fred Hutchinson Cancer Research Center, WA 98109, USA. Broome EH; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Ball ED; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, Blood and Marrow Transplantation Division, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. van der Horst EH; Igenica Biotherapeutics Inc., Burlingame, CA 94010, USA. Ginsberg MH; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic address: . Reya T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic address: .
Pokaż więcej
Źródło:
Cancer cell [Cancer Cell] 2016 Nov 14; Vol. 30 (5), pp. 792-805. Date of Electronic Publication: 2016 Oct 27.
Small, abnormal B lymphoid blast populations in chronic myelogenous leukemia at diagnosis: Does this finding indicate an accelerated course?
Autorzy:
Soma L; Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, 98109. . OehlerVG; Department of Hematology-Oncology, University of Washington Medical Center, Seattle, Washington, 98109. Ding C; Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, 98109. Cherian S; Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, 98109.
Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia.
Autorzy:
Brehme M; Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52062 Aachen, Germany. Koschmieder S; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany. Montazeri M; Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52062 Aachen, Germany. Copland M; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow G12 0ZD, United Kingdom. OehlerVG; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Radich JP; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Brümmendorf TH; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany. Schuppert A; Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52062 Aachen, Germany.; Aachen Institute for Advanced Study in Computational Engineering Science (AICES), RWTH Aachen University, 52062 Aachen, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2016 Apr 06; Vol. 6, pp. 24057. Date of Electronic Publication: 2016 Apr 06.
Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia.
Autorzy:
Kwon HY; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Soonchunhyang Institute of Medi-bio Science, Soonchunhyang University, Asan-si, Chungcheongnamdo 336-745, South Korea. Bajaj J; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA. Ito T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA. Blevins A; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA. Konuma T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA. Weeks J; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA. Lytle NK; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA. Koechlein CS; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA. Rizzieri D; Division of Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Chuah C; Department of Haematology, Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore 169857. OehlerVG; Clinical Research Division, Fred Hutchinson Cancer Research Center, WA 98109, USA. Sasik R; Center for Computational Biology and Bioinformatics, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Hardiman G; Computational Science Research Center and Biomedical Informatics Research Center, San Diego State University, San Diego, CA 92182, USA.; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Reya T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA.
Pokaż więcej
Źródło:
Cell stem cell [Cell Stem Cell] 2015 Aug 06; Vol. 17 (2), pp. 152-164. Date of Electronic Publication: 2015 Jul 23.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.
Autorzy:
Huang JC; 1] Division of Hematology, Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA [2] Division of Gerontology & Geriatric Medicine, University of Washington, Seattle, WA, USA. Basu SK; Section of Hematology & Oncology, West Virginia University School of Medicine, Morgantown, WV, USA. Zhao X; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Chien S; Division of Hematology, Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA. Fang M; 1] Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Department of Pathology and Laboratory Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA. OehlerVG; 1] Division of Hematology, Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA [2] Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Appelbaum FR; 1] Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. Becker PS; 1] Division of Hematology, Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA [2] Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2015 Apr 10; Vol. 5, pp. e302. Date of Electronic Publication: 2015 Apr 10.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia.
Autorzy:
Zimdahl B; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. [3] Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA. [4]. Ito T; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. [3]. Blevins A; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. Bajaj J; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. Konuma T; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. Weeks J; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. Koechlein CS; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. Kwon HY; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. Arami O; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. Rizzieri D; Division of Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. Broome HE; 1] Department of Pathology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, California, USA. Chuah C; 1] Department of Haematology, Singapore General Hospital, Singapore. [2] Cancer and Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School, Singapore. OehlerVG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Sasik R; Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA. Hardiman G; 1] Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Computational Science Research Center and Biomedical Informatics Research Center, San Diego State University, San Diego, California, USA. Reya T; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. [3] Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA. [4] Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, California, USA.
Pokaż więcej
Źródło:
Nature genetics [Nat Genet] 2014 Mar; Vol. 46 (3), pp. 245-52. Date of Electronic Publication: 2014 Feb 02.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies